{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["anticancer", "anticancer antibiotics", "anticancer enzymes", "bacteria", "bacterial toxins", "bacteriocins", "nonribosomal peptides", "proteins"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "29710857", "DateRevised": {"Year": "2020", "Month": "09", "Day": "30"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "04", "Day": "30"}], "Language": ["eng"], "ELocationID": ["54", "10.3390/pharmaceutics10020054"], "Journal": {"ISSN": "1999-4923", "JournalIssue": {"Volume": "10", "Issue": "2", "PubDate": {"Year": "2018", "Month": "Apr", "Day": "30"}}, "Title": "Pharmaceutics", "ISOAbbreviation": "Pharmaceutics"}, "ArticleTitle": "Anticancer Activity of Bacterial Proteins and Peptides.", "Abstract": {"AbstractText": ["Despite much progress in the diagnosis and treatment of cancer, tumour diseases constitute one of the main reasons of deaths worldwide. The side effects of chemotherapy and drug resistance of some cancer types belong to the significant current therapeutic problems. Hence, searching for new anticancer substances and medicines are very important. Among them, bacterial proteins and peptides are a promising group of bioactive compounds and potential anticancer drugs. Some of them, including anticancer antibiotics (actinomycin D, bleomycin, doxorubicin, mitomycin C) and diphtheria toxin, are already used in the cancer treatment, while other substances are in clinical trials (e.g., p28, arginine deiminase ADI) or tested in in vitro research. This review shows the current literature data regarding the anticancer activity of proteins and peptides originated from bacteria: antibiotics, bacteriocins, enzymes, nonribosomal peptides (NRPs), toxins and others such as azurin, p28, Entap and Pep27anal2. The special attention was paid to the still poorly understood active substances obtained from the marine sediment bacteria. In total, 37 chemical compounds or groups of compounds with antitumor properties have been described in the present article."]}, "AuthorList": [{"Identifier": ["0000-0001-6599-9204"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Genetics and Pharmaceutical Microbiology, Pozna\u0144 University of Medical Sciences, \u015awi\u0119cickiego 4, 60-781 Pozna\u0144, Poland. tkarpin@ump.edu.pl."}], "LastName": "Karpi\u0144ski", "ForeName": "Tomasz M", "Initials": "TM"}, {"Identifier": ["0000-0002-1738-953X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Botany, Breeding and Agricultural Technology of Medicinal Plants, Institute of Natural Fibres and Medicinal Plants, Kolejowa 2, 62-064 Plewiska, Poland. artur.adamczak@iwnirz.pl."}], "LastName": "Adamczak", "ForeName": "Artur", "Initials": "A"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmaceutics", "NlmUniqueID": "101534003", "ISSNLinking": "1999-4923"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer; Lyon, France: 2013."}, {"Citation": "Worldwide Cancer Statistics.  [(accessed on 16 January 2018)]; Available online:  http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer."}, {"Citation": "Cancer.  [(accessed on 16 January 2018)]; Available online:  http://www.who.int/mediacentre/factsheets/fs297/en/"}, {"Citation": "Cancer Prevention and Control in the Context of an Integrated Approach.  [(accessed on 16 January 2018)]; WHA70.12. Available online:  http://apps.who.int/medicinedocs/documents/s23233en/s23233en.pdf."}, {"Citation": "Langie S.A., Koppen G., Desaulniers D., Al-Mulla F., Al-Temaimi R., Amedei A., Azqueta A., Bisson W.H., Brown D.G., Brunborg G., et al. Causes of genome instability: The effect of low dose chemical exposures in modern society. Carcinogenesis. 2015;36(Suppl. 1):S61\u2013S88. doi: 10.1093/carcin/bgv031.", "ArticleIdList": ["10.1093/carcin/bgv031", "PMC4565613", "26106144"]}, {"Citation": "Kuno T., Tsukamoto T., Hara A., Tanaka T. Cancer chemoprevention through the induction apoptosis by natural compounds. J. Biophys. Chem. 2012;3:156\u2013173. doi: 10.4236/jbpc.2012.32018.", "ArticleIdList": ["10.4236/jbpc.2012.32018"]}, {"Citation": "Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646\u2013674. doi: 10.1016/j.cell.2011.02.013.", "ArticleIdList": ["10.1016/j.cell.2011.02.013", "21376230"]}, {"Citation": "Raguz S., Yag\u00fce E. Resistance to chemotherapy: New treatments and novel insights into an old problem. Br. J. Cancer. 2008;99:387\u2013391. doi: 10.1038/sj.bjc.6604510.", "ArticleIdList": ["10.1038/sj.bjc.6604510", "PMC2527800", "18665178"]}, {"Citation": "Coley W.B. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and Bacillus prodigiosus) Proc. R. Soc. Med. Surg. 1909;3:1\u201348.", "ArticleIdList": ["PMC1961042", "19974799"]}, {"Citation": "Patyar S., Joshi R., Prasad Byrav D.S., Prakash A., Medhi B., Das B.K. Bacteria in cancer therapy: A novel experimental strategy. J. Biomed. Sci. 2010;17:21. doi: 10.1186/1423-0127-17-21.", "ArticleIdList": ["10.1186/1423-0127-17-21", "PMC2854109", "20331869"]}, {"Citation": "Encyclopaedia Britannica.  [(accessed on 20 February 2018)]; Available online:  http://www.britannica.com/science/antibiotic."}, {"Citation": "Barret J.M., Salles B., Provot C., Hill B.T. Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplate assay. Carcinogenesis. 1997;18:2441\u20132445. doi: 10.1093/carcin/18.12.2441.", "ArticleIdList": ["10.1093/carcin/18.12.2441", "9450493"]}, {"Citation": "Wu C.H., Pan J.S., Chang W.C., Hung J.S., Mao S.J. The molecular mechanism of actinomycin D in preventing neointimal formation in rat carotid arteries after balloon injury. J. Biomed. Sci. 2005;12:503\u2013512. doi: 10.1007/s11373-005-6900-5.", "ArticleIdList": ["10.1007/s11373-005-6900-5", "15959627"]}, {"Citation": "Koba M., Konopa J. Actinomycin D and its mechanisms of action. Postepy Hig. Med. Dosw. 2005;59:290\u2013298. (In Polish)", "ArticleIdList": ["15995596"]}, {"Citation": "Cosmegen\u00ae for Injection.  [(accessed on 20 February 2018)]; Available online:  http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050682s025lbl.pdf."}, {"Citation": "Segerman Z.J., Roy B., Hecht S.M. Characterization of bleomycin-mediated cleavage of a hairpin DNA library. Biochemistry. 2013;52 doi: 10.1021/bi400779r.", "ArticleIdList": ["10.1021/bi400779r", "PMC3859804", "23834496"]}, {"Citation": "Bayer R.A., Gaynor E.R., Fisher R.I. Bleomycin in non-Hodgkin\u2019s lymphoma. Semin. Oncol. 1992;19(Suppl. 5):46\u201353.", "ArticleIdList": ["1384144"]}, {"Citation": "Chen J.K., Yang D., Shen B., Murray V. Bleomycin analogues preferentially cleave at the transcription start sites of actively transcribed genes in human cells. Int. J. Biochem. Cell Biol. 2017;85:56\u201365. doi: 10.1016/j.biocel.2017.02.001.", "ArticleIdList": ["10.1016/j.biocel.2017.02.001", "28167289"]}, {"Citation": "Genomics of Drug Sensitivity in Cancer;  [(accessed on 14 April 2018)]. Bleomycin. Available online:  http://www.cancerrxgene.org/translation/Drug/190."}, {"Citation": "Abraham S.A., Waterhouse D.N., Mayer L.D., Cullis P.R., Madden T.D., Bally M.B. The liposomal formulation of doxorubicin. Methods Enzymol. 2005;391:71\u201396. doi: 10.1016/S0076-687991004-5.", "ArticleIdList": ["10.1016/S0076-687991004-5", "15721375"]}, {"Citation": "Botlagunta M., Kollapalli B., Kakarla L., Gajarla S.P., Gade S.P., Dadi C.L., Penumadu A., Javeed S. In vitro anti-cancer activity of doxorubicin against human RNA helicase, DDX3. Bioinformation. 2016;12:347\u2013353. doi: 10.6026/97320630012347.", "ArticleIdList": ["10.6026/97320630012347", "PMC5311078", "28246464"]}, {"Citation": "Vittorio O., Le Grand M., Makharza S.A., Curcio M., Tucci P., Iemma F., Nicoletta F.P., Hampel S., Cirillo G. Doxorubicin synergism and resistance reversal in human neuroblastoma BE(2)C cell lines: An in vitro study with dextran-catechin nanohybrids. Eur. J. Pharm. Biopharm. 2018;122:176\u2013185. doi: 10.1016/j.ejpb.2017.11.005.", "ArticleIdList": ["10.1016/j.ejpb.2017.11.005", "29129733"]}, {"Citation": "Doxorubicin Hydrochloride for Injection, USP.  [(accessed on 20 February 2018)]; Available online:  http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050467s070lbl.pdf."}, {"Citation": "Mitomycin C from Streptomyces caespitosus.  [(accessed on 20 February 2018)]; Available online:  http://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Product_Information_Sheet/2/m0503pis.pdf."}, {"Citation": "Bradner W.T. Mitomycin C: A clinical update. Cancer Treat. Rev. 2001;27:35\u201350. doi: 10.1053/ctrv.2000.0202.", "ArticleIdList": ["10.1053/ctrv.2000.0202", "11237776"]}, {"Citation": "Genomics of Drug Sensitivity in Cancer;  [(accessed on 14 April 2018)]. Mitomycin-C. Available online:  http://www.cancerrxgene.org/translation/Drug/136."}, {"Citation": "Latta V.D., Cecchettini A., Del Ry S., Morales M.A. Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions. Pharmacol. Res. 2015;97:122\u2013130. doi: 10.1016/j.phrs.2015.04.012.", "ArticleIdList": ["10.1016/j.phrs.2015.04.012", "25959210"]}, {"Citation": "Farhane Z., Bonnier F., Byrne H.J. An in vitro study of the interaction of the chemotherapeutic drug Actinomycin D with lung cancer cell lines using Raman micro-spectroscopy. J. Biophotonics. 2018;11:e201700112. doi: 10.1002/jbio.201700112.", "ArticleIdList": ["10.1002/jbio.201700112", "28703437"]}, {"Citation": "D\u2019Arpa P., Liu L.F. Topoisomerase\u2014Targeting antitumor drugs. Biochim. Biophys. Acta. 1989;989:163\u2013177. doi: 10.1016/0304-419X(89)90041-3.", "ArticleIdList": ["10.1016/0304-419X(89)90041-3", "2557085"]}, {"Citation": "Dactinomycine.  [(accessed on 20 February 2018)]; Available online:  http://medycyna.anauk.net/101-0-393-.Encyklopedia.Lekow.html."}, {"Citation": "Egger C., Cannet C., G\u00e9rard C., Jarman E., Jarai G., Feige A., Suply T., Micard A., Dunbar A., Tigani B., et al. Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology. PLoS ONE. 2013;8:e63432. doi: 10.1371/journal.pone.0063432.", "ArticleIdList": ["10.1371/journal.pone.0063432", "PMC3646779", "23667616"]}, {"Citation": "Blenoxane.  [(accessed on 20 February 2018)]; Available online:  http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf."}, {"Citation": "Bleomycin for Injection USP.  [(accessed on 20 February 2018)]; Available online:  http://oncozine.com/wp-content/uploads/2017/07/Bleomycin-for-Injection-USP.pdf."}, {"Citation": "Thorn C.F., Oshiro C., Marsh S., Hernandez-Boussard T., McLeod H., Klein T.E., Altman R.B. Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet. Genom. 2011;21:440\u2013446. doi: 10.1097/FPC.0b013e32833ffb56.", "ArticleIdList": ["10.1097/FPC.0b013e32833ffb56", "PMC3116111", "21048526"]}, {"Citation": "Cagel M., Grotz E., Bernabeu E., Moretton M.A., Chiappetta D.A. Doxorubicin: Nanotechnological overviews from bench to bedside. Drug Discov. Today. 2017;22:270\u2013281. doi: 10.1016/j.drudis.2016.11.005.", "ArticleIdList": ["10.1016/j.drudis.2016.11.005", "27890669"]}, {"Citation": "Preet S., Bharati S., Panjeta A., Tewari R., Rishi P. Effect of nisin and doxorubicin on DMBA-induced skin carcinogenesis\u2014A possible adjunct therapy. Tumour Biol. 2015;36:8301\u20138308. doi: 10.1007/s13277-015-3571-3.", "ArticleIdList": ["10.1007/s13277-015-3571-3", "26002579"]}, {"Citation": "Doksorubicyna (Opis Profesjonalny)  [(accessed on 20 February 2018)]; Available online:  http://bazalekow.mp.pl/leki/doctor_subst.html?id=247."}, {"Citation": "Verweij J., Pinedo H.M. Mitomycin C: Mechanism of action, usefulness and limitations. Anti-Cancer Drugs. 1990;1:5\u201313. doi: 10.1097/00001813-199010000-00002.", "ArticleIdList": ["10.1097/00001813-199010000-00002", "2131038"]}, {"Citation": "Mitomycin.  [(accessed on 20 February 2018)]; Available online:  http://bazalekow.mp.pl/leki/szukaj.html?item_name=mitomycin."}, {"Citation": "Karpi\u0144ski T.M., Szkaradkiewicz A.K. Bacteriocins. In: Caballero B., Finglas P.M., Toldra F., editors. Encyclopedia of Food and Health. Volume 1. Elsevier, Academic Press; New York, NY, USA: 2016. pp. 312\u2013319."}, {"Citation": "Kaur S., Kaur S. Bacteriocins as potential anticancer agents. Front. Pharmacol. 2015;6:272. doi: 10.3389/fphar.2015.00272.", "ArticleIdList": ["10.3389/fphar.2015.00272", "PMC4639596", "26617524"]}, {"Citation": "Mandal S.M., Pati B.R., Chakraborty R., Franco O.L. New insights into the bioactivity of peptides from probiotics. Front. Biosci. 2016;8:450\u2013459. doi: 10.2741/e779.", "ArticleIdList": ["10.2741/e779", "27100351"]}, {"Citation": "Drider D., Bendali F., Naghmouchi K., Chikindas M.L. Bacteriocins: Not only antibacterial agents. Probiotics Antimicrob. Proteins. 2016;8:177\u2013182. doi: 10.1007/s12602-016-9223-0.", "ArticleIdList": ["10.1007/s12602-016-9223-0", "27481236"]}, {"Citation": "Alvarez-Sieiro P., Montalb\u00e1n-L\u00f3pez M., Mu D., Kuipers O.P. Bacteriocins of lactic acid bacteria: Extending the family. Appl. Microbiol. Biotechnol. 2016;100:2939\u20132951. doi: 10.1007/s00253-016-7343-9.", "ArticleIdList": ["10.1007/s00253-016-7343-9", "PMC4786598", "26860942"]}, {"Citation": "Gomes K.M., Duarte R.S., de Freire Bastos M.D. Lantibiotics produced by Actinobacteria and their potential applications (a review) Microbiology. 2017;163:109\u2013121. doi: 10.1099/mic.0.000397.", "ArticleIdList": ["10.1099/mic.0.000397", "28270262"]}, {"Citation": "Karpi\u0144ski T.M., Szkaradkiewicz A.K. Characteristic of bacteriocines and their application. Pol. J. Microbiol. 2013;62:223\u2013235.", "ArticleIdList": ["24459827"]}, {"Citation": "Paiva A.D., de Oliveira M.D., de Paula S.O., Baracat-Pereira M.C., Breukink E., Mantovani H.C. Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activity. Microbiology. 2012;158:2851\u20132858. doi: 10.1099/mic.0.062190-0.", "ArticleIdList": ["10.1099/mic.0.062190-0", "22956757"]}, {"Citation": "Chumchalova J., Smarda J. Human tumor cells are selectively inhibited by colicins. Folia Microbiol. 2003;48:111\u2013115. doi: 10.1007/BF02931286.", "ArticleIdList": ["10.1007/BF02931286", "12744087"]}, {"Citation": "Baindara P., Gautam A., Raghava G.P.S., Korpole S. Anticancer properties of a defensin like class IId bacteriocin Laterosporulin10. Sci. Rep. 2017;7:46541. doi: 10.1038/srep46541.", "ArticleIdList": ["10.1038/srep46541", "PMC5396196", "28422156"]}, {"Citation": "Hetz C., Bono M.R., Barros L.F., Lagos R. Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines. Proc. Natl. Acad. Sci. USA. 2002;99:2696\u20132701. doi: 10.1073/pnas.052709699.", "ArticleIdList": ["10.1073/pnas.052709699", "PMC122410", "11880624"]}, {"Citation": "Lagos R., Tello M., Mercado G., Garc\u00eda V., Monasterio O. Antibacterial and antitumorigenic properties of microcin E492, a pore-forming bacteriocin. Curr. Pharm. Biotechnol. 2009;10:74\u201385. doi: 10.2174/138920109787048643.", "ArticleIdList": ["10.2174/138920109787048643", "19149591"]}, {"Citation": "Begde D., Bundale S., Mashitha P., Rudra J., Nashikkar N., Upadhyay A. Immunomodulatory efficacy of nisin\u2014A bacterial lantibiotic peptide. J. Pept. Sci. 2011;17:438\u2013444. doi: 10.1002/psc.1341.", "ArticleIdList": ["10.1002/psc.1341", "21294231"]}, {"Citation": "Joo N.E., Ritchie K., Kamarajan P., Miao D., Kapila Y.L. Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1. Cancer Med. 2012;1:295\u2013305. doi: 10.1002/cam4.35.", "ArticleIdList": ["10.1002/cam4.35", "PMC3544465", "23342279"]}, {"Citation": "Kamarajan P., Hayami T., Matte B., Liu Y., Danciu T., Ramamoorthy A., Worden F., Kapila S., Kapila Y. Nisin ZP a bacteriocin and food preservative, inhibits head and neck cancer tumorigenesis and prolongs survival. PLoS ONE. 2015;10:e0131008. doi: 10.1371/journal.pone.0131008.", "ArticleIdList": ["10.1371/journal.pone.0131008", "PMC4489501", "26132406"]}, {"Citation": "Balgir P.P., Bhatia P., Kaur B. Sequence analysis and homology based modeling to assess structure-function relationship of pediocin CP2 of Pediococcus acidilactici MTCC 5101. Ind. J. Biotechnol. 2010;9:431\u2013434."}, {"Citation": "Kumar B., Balgir P.P., Kaur B., Mittu B., Chauhan A. In vitro cytotoxicity of native and rec-pediocin CP2 against cancer cell lines: A comparative study. Pharm. Anal. Acta. 2012;3:1000183. doi: 10.4172/2153-2435.1000183.", "ArticleIdList": ["10.4172/2153-2435.1000183"]}, {"Citation": "Villarante K.I., Elegado F.B., Iwatani S., Zendo T., Sonomoto K., de Guzman E.E. Purification, characterization and in vitro cytotoxicity of the bacteriocin from Pediococcus acidilactici K2a2-3 against human colon adenocarcinoma (HT29) and human cervical carcinoma (HeLa) cells. World J. Microbiol. Biotechnol. 2011;27:975\u2013980. doi: 10.1007/s11274-010-0541-1.", "ArticleIdList": ["10.1007/s11274-010-0541-1"]}, {"Citation": "Zhao H., Sood R., Jutila A., Bose S., Fimland G., Nissen-Meyer J., Kinnunen P.K. Interaction of the antimicrobial peptide pheromone plantaricin A with model membranes: Implications for a novel mechanism of action. Biochim. Biophys. Acta. 2006;1758:1461\u20131474. doi: 10.1016/j.bbamem.2006.03.037.", "ArticleIdList": ["10.1016/j.bbamem.2006.03.037", "16806056"]}, {"Citation": "Abdi-Ali A., Worobec E.A., Deezagi A., Malekzadeh F. Cytotoxic effects of pyocin S2 produced by Pseudomonas aeruginosa on the growth of three human cell lines. Can. J. Microbiol. 2004;50:375\u2013381. doi: 10.1139/w04-019.", "ArticleIdList": ["10.1139/w04-019", "15213746"]}, {"Citation": "Watanabe T., Saito H. Cytotoxicity of pyocin S2 to tumor and normal cells and its interaction with cell surfaces. Biochim. Biophys. Acta. 1980;633:77\u201386. doi: 10.1016/0304-4165(80)90039-2.", "ArticleIdList": ["10.1016/0304-4165(80)90039-2", "6256005"]}, {"Citation": "Bactibase.  [(accessed on 12 February 2018)]; Available online:  http://bactibase.hammamilab.org."}, {"Citation": "Uniprot.  [(accessed on 12 February 2018)]; Available online:  http://www.uniprot.org."}, {"Citation": "Swiss-Model.  [(accessed on 12 February 2018)]; Available online:  http://swissmodel.expasy.org."}, {"Citation": "Kiefer F., Arnold K., K\u00fcnzli M., Bordoli L., Schwede T. The SWISS-MODEL Repository and associated resources. Nucleic Acids Res. 2009;37:D387\u2013D392. doi: 10.1093/nar/gkn750.", "ArticleIdList": ["10.1093/nar/gkn750", "PMC2686475", "18931379"]}, {"Citation": "Smarda J., Fialova M., Smarda J., Jr. Cytotoxic effects of colicins E1 and E3 on v-myb-transformed chicken monoblasts. Folia Biol. 2001;47:11\u201313.", "ArticleIdList": ["11232863"]}, {"Citation": "Michel-Briand Y., Baysse C. The pyocins of Pseudomonas aeruginosa. Biochimie. 2002;84:499\u2013510. doi: 10.1016/S0300-9084(02)01422-0.", "ArticleIdList": ["10.1016/S0300-9084(02)01422-0", "12423794"]}, {"Citation": "Ni Y., Schwaneberg U., Sun Z.H. Arginine deiminase, a potential anti-tumor drug. Cancer Lett. 2008;261:1\u201311. doi: 10.1016/j.canlet.2007.11.038.", "ArticleIdList": ["10.1016/j.canlet.2007.11.038", "18179862"]}, {"Citation": "Glazer E.S., Piccirillo M., Albino V., Di Giacomo R., Palaia R., Mastro A.A., Beneduce G., Castello G., De Rosa V., Petrillo A., et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J. Clin. Oncol. 2010;28:2220\u20132226. doi: 10.1200/JCO.2009.26.7765.", "ArticleIdList": ["10.1200/JCO.2009.26.7765", "20351325"]}, {"Citation": "Kim R.H., Coates J.M., Bowles T.L., McNerney G.P., Sutcliffe J., Jung J.U., Gandour-Edwards R., Chuang F.Y.S., Bold R.J., Kung H.-J. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res. 2009;69:2. doi: 10.1158/0008-5472.CAN-08-3157.", "ArticleIdList": ["10.1158/0008-5472.CAN-08-3157", "PMC2629384", "19147587"]}, {"Citation": "Fiedler T., Strauss M., Hering S., Redanz U., William D., Rosche Y., Classen C.F., Kreikemeyer B., Linnebacher M., Maletzki C. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo. Cancer Biol. Ther. 2015;16:1047\u20131055. doi: 10.1080/15384047.2015.1026478.", "ArticleIdList": ["10.1080/15384047.2015.1026478", "PMC4623118", "25774632"]}, {"Citation": "Kaur B., Kaur R. Purification of a dimeric arginine deiminase from Enterococcus faecium GR7 and study of its anti-cancerous activity. Protein Expr. Purif. 2016;125:53\u201360. doi: 10.1016/j.pep.2015.09.011.", "ArticleIdList": ["10.1016/j.pep.2015.09.011", "26363115"]}, {"Citation": "Pritsa A.A., Papazisis K.T., Kortsaris A.H., Geromichalos G.D., Kyriakidis Antitumor activity of l-asparaginase from Thermus thermophilus. Anticancer Drugs. 2001;12:137\u2013142. doi: 10.1097/00001813-200102000-00007.", "ArticleIdList": ["10.1097/00001813-200102000-00007", "11261887"]}, {"Citation": "Avramis V.I., Sencer S., Periclou A.P., Sather H., Bostrom B.C., Cohen L.J., Ettinger A.G., Ettinger L.J., Franklin J., Gaynon P.S., et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children\u2019s Cancer Group study. Blood. 2002;99:1986\u20131994. doi: 10.1182/blood.V99.6.1986.", "ArticleIdList": ["10.1182/blood.V99.6.1986", "11877270"]}, {"Citation": "Panosyan E.H., Wang Y., Xia P., Lee W.N., Pak Y., Laks D.R., Lin H.J., Moore T.B., Cloughesy T.F., Kornblum H.I., et al. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors. Mol. Cancer Res. 2014;12:694\u2013702. doi: 10.1158/1541-7786.MCR-13-0576.", "ArticleIdList": ["10.1158/1541-7786.MCR-13-0576", "PMC4020976", "24505127"]}, {"Citation": "Jaccard A., Gachard N., Marin B., Rogez S., Audrain M., Suarez F., Tilly H., Morschhauser F., Thieblemont C., Ysebaert L., et al. Efficacy of l-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117:1834\u20131839. doi: 10.1182/blood-2010-09-307454.", "ArticleIdList": ["10.1182/blood-2010-09-307454", "21123825"]}, {"Citation": "Covini D., Tardito S., Bussolati O., Chiarelli L.R., Pasquetto M.V., Digilio R., Valentini G., Scotti C. Expanding targets for a metabolic therapy of cancer: l-asparaginase. Recent Pat. Anti-Cancer Drug Discov. 2012;7:4\u201313. doi: 10.2174/157489212798358001.", "ArticleIdList": ["10.2174/157489212798358001", "21854356"]}, {"Citation": "Yu M., Henning R., Walker A., Kim G., Perroy A., Alessandro R., Virador V., Kohn E.C. l-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. J. Cell. Mol. Med. 2012;16:2369\u20132378. doi: 10.1111/j.1582-4934.2012.01547.x.", "ArticleIdList": ["10.1111/j.1582-4934.2012.01547.x", "PMC3416969", "22333033"]}, {"Citation": "Oza V.P., Parmar P.P., Kumar S., Subramanian R.B. Anticancer properties of highly purified l-asparaginase from Withania somnifera L. against acute lymphoblastic leukemia. Appl. Biochem. Biotechnol. 2010;160:1833\u20131840. doi: 10.1007/s12010-009-8667-z.", "ArticleIdList": ["10.1007/s12010-009-8667-z", "19448978"]}, {"Citation": "Meghavarnam A.K., Salah M., Sreepriya M., Janakiraman S. Growth inhibitory and proapoptotic effects of l-asparaginase from Fusarium culmorum ASP-87 on human leukemia cells (Jurkat) Fundam. Clin. Pharmacol. 2017;31:292\u2013300. doi: 10.1111/fcp.12257.", "ArticleIdList": ["10.1111/fcp.12257", "27885727"]}, {"Citation": "Arjun J.K., Aneesh B.P., Kavitha T., Harikrishnan K. Characterization of a novel asparaginase from soil metagenomic libraries generated from forest soil. Biotechnol. Lett. 2018;40:343\u2013348. doi: 10.1007/s10529-017-2470-7.", "ArticleIdList": ["10.1007/s10529-017-2470-7", "29127643"]}, {"Citation": "Takaku H., Takase M., Abe S., Hayashi H., Miyazaki K. In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini. Int. J. Cancer. 1992;51:244\u2013249. doi: 10.1002/ijc.2910510213.", "ArticleIdList": ["10.1002/ijc.2910510213", "1568792"]}, {"Citation": "Holtsberg F.W., Ensor C.M., Steiner M.R., Bomalaski J.S., Clark M.A. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: Effects of PEG formulations on its pharmacological properties. J. Controll. Release. 2002;80:259\u2013271. doi: 10.1016/S0168-3659(02)00042-1.", "ArticleIdList": ["10.1016/S0168-3659(02)00042-1", "11943403"]}, {"Citation": "Pieters R., Hunger S.P., Boos J., Rizzari C., Silverman L., Baruchel A., Goekbuget N., Schrappe M., Pui C.H. l-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer. 2011;117:238\u2013249. doi: 10.1002/cncr.25489.", "ArticleIdList": ["10.1002/cncr.25489", "PMC3000881", "20824725"]}, {"Citation": "Agrawal S., Acharya D., Adholeya A., Barrow C.J., Deshmukh S.K. Nonribosomal peptides from marine microbes and their antimicrobial and anticancer potential. Front. Pharmacol. 2017;8:828. doi: 10.3389/fphar.2017.00828.", "ArticleIdList": ["10.3389/fphar.2017.00828", "PMC5702503", "29209209"]}, {"Citation": "Sieber S.A., Marahiel M.A. Learning from nature\u2019s drug factories: Nonribosomal synthesis of macrocyclic peptides. J. Bacteriol. 2003;185:7036\u20137043. doi: 10.1128/JB.185.24.7036-7043.2003.", "ArticleIdList": ["10.1128/JB.185.24.7036-7043.2003", "PMC296262", "14645262"]}, {"Citation": "Asolkar R.N., Freel K.C., Jensen P.R., Fenical W., Kondratyuk T.P., Park E.-J., Pezzuto J.M. Arenamides A-C, cytotoxic NF\u03baB inhibitors from the marine actinomycete Salinispora arenicola. J. Nat. Prod. 2009;72:396\u2013402. doi: 10.1021/np800617a.", "ArticleIdList": ["10.1021/np800617a", "PMC2837138", "19117399"]}, {"Citation": "Oku N., Adachi K., Matsuda S., Kasai H., Takatsuki A., Shizuri Y. Ariakemicins A and B, novel polyketide-peptide antibiotics from a marine gliding bacterium of the genus Rapidithrix. Org. Lett. 2008;10:2481\u20132484. doi: 10.1021/ol8007292.", "ArticleIdList": ["10.1021/ol8007292", "18498148"]}, {"Citation": "Yang L., Tan R.-X., Wang Q., Huang W.-Y., Yin Y.-X. Antifungal cyclopeptides from Halobacillus litoralis YS3106 of marine origin. Tetrahedron Lett. 2002;43:6545\u20136548. doi: 10.1016/S0040-4039(02)01458-2.", "ArticleIdList": ["10.1016/S0040-4039(02)01458-2"]}, {"Citation": "Kalinovskaya N.I., Romanenko L.A., Kalinovsky A.I., Dmitrenok P.S., Dyshlovoy S.A. A new antimicrobial and anticancer peptide producing by the marine deep sediment strain \u201cPaenibacillus profundus\u201d sp. nov. Sl 79. Nat. Prod. Commun. 2013;8:381\u2013384.", "ArticleIdList": ["23678816"]}, {"Citation": "Tareq F.S., Kim J.H., Lee M.A., Lee H.-S., Lee Y.-J., Lee J.S., Shin H.J. Ieodoglucomides A and B from a marine-derived bacterium Bacillus licheniformis. Org. Lett. 2012;14:1464\u20131467. doi: 10.1021/ol300202z.", "ArticleIdList": ["10.1021/ol300202z", "22360451"]}, {"Citation": "Ma Z., Wang N., Hu J., Wang S. Isolation and characterization of a new iturinic lipopeptide, mojavensin A produced by a marine-derived bacterium Bacillus mojavensis B0621A. J. Antibiot. 2012;65:317\u2013322. doi: 10.1038/ja.2012.19.", "ArticleIdList": ["10.1038/ja.2012.19", "22491138"]}, {"Citation": "Rama M.R., Teisan S., White D.J., Nicholson B., Grodberg J., Neuteboom S.T.C., Lam K.S., Mosca D.A., Lloyd K.G., Potts B.C.M. Lajollamycin, a nitro-tetraene spiro-\u03b2-lactone-\u03b3-lactam antibiotic from the marine actinomycete Streptomyces nodosus. J. Nat. Prod. 2005;68:240\u2013243. doi: 10.1021/np049725x.", "ArticleIdList": ["10.1021/np049725x", "15730252"]}, {"Citation": "Cho J.Y., Williams P.G., Kwon H.C., Jensen P.R., Fenical W. Lucentamycins A-D, cytotoxic peptides from the marine-derived actinomycete Nocardiopsis lucentensis. J. Nat. Prod. 2007;70:1321\u20131328. doi: 10.1021/np070101b.", "ArticleIdList": ["10.1021/np070101b", "17630797"]}, {"Citation": "Kanoh K., Matsuo Y., Adachi K., Imagawa H., Nishizawa M., Shizuri Y. Mechercharmycins A and B, cytotoxic substances from marine-derived Thermoactinomyces sp. YM3-251. J. Antibiot. 2005;58:289\u2013292. doi: 10.1038/ja.2005.36.", "ArticleIdList": ["10.1038/ja.2005.36", "15981418"]}, {"Citation": "Zhang H.L., Hua H.M., Pei Y.H., Yao X.S. Three new cytotoxic cyclic acylpeptides from marine Bacillus sp. Chem. Pharm. Bull. 2004;52:1029\u20131030. doi: 10.1248/cpb.52.1029.", "ArticleIdList": ["10.1248/cpb.52.1029", "15305011"]}, {"Citation": "Um S., Choi T.J., Kim H., Kim B.Y., Kim S.-H., Lee S.K., Oh K.-B., Shin J., Oh D.-C. Ohmyungsamycins A and B: Cytotoxic and antimicrobial cyclic peptides produced by Streptomyces sp. from a volcanic island. J. Org. Chem. 2013;78:12321\u201312329. doi: 10.1021/jo401974g.", "ArticleIdList": ["10.1021/jo401974g", "24266328"]}, {"Citation": "Williams D.E., Dalisay D.S., Patrick B.O., Matainaho T., Andrusiak K., Deshpande R., Myers C.L., Piotrowski J.S., Boone C., Yoshida M., et al. Padanamides A and B, highly modified linear tetrapeptides produced in culture by a Streptomyces sp. isolated from a marine sediment. Org. Lett. 2011;13:3936\u20133939. doi: 10.1021/ol2014494.", "ArticleIdList": ["10.1021/ol2014494", "PMC3152301", "21749075"]}, {"Citation": "Miller E.D., Kauffman C.A., Jensen P.R., Fenical W. Piperazimycins: Cytotoxic hexadepsipeptides from a marine-derived bacterium of the genus Streptomyces. J. Org. Chem. 2007;72:323\u2013330. doi: 10.1021/jo061064g.", "ArticleIdList": ["10.1021/jo061064g", "17221946"]}, {"Citation": "Fiedler H.-P., Bruntner C., Riedlinger J., Bull A.T., Knutsen G., Goodfellow M., Jones A., Maldonado L., Pathom-aree W., Beil W., et al. Proximicin A, B and C, novel aminofuran antibiotic and anticancer compounds isolated from marine strains of the actinomycete Verrucosispora. J. Antibiot. 2008;61:158\u2013163. doi: 10.1038/ja.2008.125.", "ArticleIdList": ["10.1038/ja.2008.125", "18503194"]}, {"Citation": "Matsuo Y., Kanoh K., Yamori T., Kasai H., Katsuta A., Adachi K., Shin-Ya K., Shizuri Y. Urukthapelstatin A, a novel cytotoxic substance from marine-derived Mechercharimyces asporophorigenens YM11-542. I. Fermentation, isolation and biological activities. J. Antibiot. 2007;60:251\u2013255. doi: 10.1038/ja.2007.30.", "ArticleIdList": ["10.1038/ja.2007.30", "17456975"]}, {"Citation": "Matsuo Y., Kanoh K., Imagawa H., Adachi K., Nishizawa M., Shizuri Y. Urukthapelstatin A, a novel cytotoxic substance from marine-derived Mechercharimyces asporophorigenens YM11-542. II. Physico-chemical properties and structural elucidation. J. Antibiot. 2007;60:256\u2013260. doi: 10.1038/ja.2007.31.", "ArticleIdList": ["10.1038/ja.2007.31", "17456976"]}, {"Citation": "Henkel J.S., Baldwin M.R., Barbieri J.T. Toxins from bacteria. EXS. 2010;100:1\u201329.", "ArticleIdList": ["PMC3564551", "20358680"]}, {"Citation": "Purkiss J.R., Friis L.M., Doward S., Quinn C.P. Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells. Neurotoxicology. 2001;22:447\u2013453. doi: 10.1016/S0161-813X(01)00042-0.", "ArticleIdList": ["10.1016/S0161-813X(01)00042-0", "11577803"]}, {"Citation": "Karsenty G., Rocha J., Chevalier S., Scarlata E., Andrieu C., Zouanat F.Z., Rocchi P., Giusiano S., Elzayat E.A., Corcos J. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. Prostate. 2009;69:1143\u20131150. doi: 10.1002/pros.20958.", "ArticleIdList": ["10.1002/pros.20958", "19399787"]}, {"Citation": "Proietti S., Nardicchi V., Porena M., Giannantoni A. Botulinum toxin type-A toxin activity on prostate cancer cell lines. Urologia. 2012;79:135\u2013141. doi: 10.5301/RU.2012.9254.", "ArticleIdList": ["10.5301/RU.2012.9254", "22610840"]}, {"Citation": "Bandala C., Perez-Santos J.L., Lara-Padilla E., Delgado Lopez G., Anaya-Ruiz M. Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line. Asian Pac. J. Cancer Prev. 2013;14:891\u2013894. doi: 10.7314/APJCP.2013.14.2.891.", "ArticleIdList": ["10.7314/APJCP.2013.14.2.891", "23621257"]}, {"Citation": "Holmes R.K. Biology and molecular epidemiology of diphtheria toxin and the tox gene. J. Infect. Dis. 2000;181(Suppl. 1):S156\u2013S167. doi: 10.1086/315554.", "ArticleIdList": ["10.1086/315554", "10657208"]}, {"Citation": "Martarelli D., Pompei P., Mazzoni G. Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197. Chemotherapy. 2009;55:425\u2013432. doi: 10.1159/000264689.", "ArticleIdList": ["10.1159/000264689", "19996587"]}, {"Citation": "Vallera D.A., Li C., Jin N., Panoskaltsis-Mortari A., Hall W.A. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J. Natl. Cancer Inst. 2002;94:597\u2013606. doi: 10.1093/jnci/94.8.597.", "ArticleIdList": ["10.1093/jnci/94.8.597", "11959893"]}, {"Citation": "Lutz M.B., Baur A.S., Schuler-Thurner B., Schuler G. Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak\u00ae on CD25+ cells. Oncoimmunology. 2014;3:e28223. doi: 10.4161/onci.28223.", "ArticleIdList": ["10.4161/onci.28223", "PMC4091105", "25050193"]}, {"Citation": "Shafiee F., Rabbani M., Jahanian-Najafabadi A. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent. J. Microbiol. Methods. 2016;130:100\u2013105. doi: 10.1016/j.mimet.2016.09.004.", "ArticleIdList": ["10.1016/j.mimet.2016.09.004", "27609715"]}, {"Citation": "Lewis D.J., Dao H., Jr., Nagarajan P., Duvic M. Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox. JAAD Case Rep. 2017;3:501\u2013504. doi: 10.1016/j.jdcr.2017.06.031.", "ArticleIdList": ["10.1016/j.jdcr.2017.06.031", "PMC5728491", "29296637"]}, {"Citation": "Alderson R.F., Kreitman R.J., Chen T., Yeung P., Herbst R., Fox J.A., Pastan I. CAT-8015: A second-generation Pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin. Cancer Res. 2009;15:832\u2013839. doi: 10.1158/1078-0432.CCR-08-1456.", "ArticleIdList": ["10.1158/1078-0432.CCR-08-1456", "PMC2742326", "19188153"]}, {"Citation": "Karpi\u0144ski T.M., Szkaradkiewicz A.K. Anticancer peptides from bacteria. Bangladesh J. Pharmacol. 2013;8:343\u2013348. doi: 10.3329/bjp.v8i3.15704.", "ArticleIdList": ["10.3329/bjp.v8i3.15704"]}, {"Citation": "Oh S., Todhunter D.A., Panoskaltsis-Mortari A., Buchsbaum D.J., Toma S., Vallera D.A. A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model. Pancreas. 2012;41:789\u2013796. doi: 10.1097/MPA.0b013e31823b5f2e.", "ArticleIdList": ["10.1097/MPA.0b013e31823b5f2e", "PMC3336038", "22258068"]}, {"Citation": "Risberg K., Fodstad O., Andersson Y. Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma. PLoS ONE. 2011;6:e24012. doi: 10.1371/journal.pone.0024012.", "ArticleIdList": ["10.1371/journal.pone.0024012", "PMC3168478", "21915275"]}, {"Citation": "Waldron N.N., Kaufman D.S., Oh S., Inde Z., Hexum M.K., Ohlfest J.R., Vallera D.A. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol. Cancer Ther. 2011;10:1829\u20131838. doi: 10.1158/1535-7163.MCT-11-0206.", "ArticleIdList": ["10.1158/1535-7163.MCT-11-0206", "PMC3191276", "21862685"]}, {"Citation": "Kerr D.E., Wu G.Y., Wu C.H., Senter P.D. Listeriolysin O potentiates immunotoxin and bleomycin cytotoxicity. Bioconjug. Chem. 1997;8:781\u2013784. doi: 10.1021/bc970124+.", "ArticleIdList": ["10.1021/bc970124+", "9404648"]}, {"Citation": "Provoda C.J., Stier E.M., Lee K.D. Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J. Biol. Chem. 2003;278:35102\u201335108. doi: 10.1074/jbc.M305411200.", "ArticleIdList": ["10.1074/jbc.M305411200", "12832408"]}, {"Citation": "V\u00e1zquez-Boland J.A., Kuhn M., Berche P., Chakraborty T., Dom\u00ednguez-Bernal G., Goebel W., Gonz\u00e1lez-Zorn B., Wehland J., Kreft J. Listeria pathogenesis and molecular virulence determinants. Clin. Microbiol. Rev. 2001;14:584\u2013640. doi: 10.1128/CMR.14.3.584-640.2001.", "ArticleIdList": ["10.1128/CMR.14.3.584-640.2001", "PMC88991", "11432815"]}, {"Citation": "Bergelt S., Frost S., Lilie H. Listeriolysin O as cytotoxic component of an immunotoxin. Protein Sci. 2009;18:1210\u20131220. doi: 10.1002/pro.130.", "ArticleIdList": ["10.1002/pro.130", "PMC2774431", "19472336"]}, {"Citation": "Stachowiak R., Lyzniak M., Budziszewska B.K., Roeske K., Bielecki J., Hoser G., Kawiak J. Cytotoxicity of bacterial metabolic products, including listeriolysin O, on leukocyte targets. J. Biomed. Biotechnol. 2012;2012:954375. doi: 10.1155/2012/954375.", "ArticleIdList": ["10.1155/2012/954375", "PMC3471067", "23091365"]}, {"Citation": "Goto M., Yamada T., Kimbara K., Horner J., Newcomb M., Gupta T.K., Chakrabarty A.M. Induction of apoptosis in macrophages by Pseudomonas aeruginosa azurin: Tumour-suppressor protein p53 and reactive oxygen species, but not redox activity, as critical elements in cytotoxicity. Mol. Microbiol. 2003;47:549\u2013559. doi: 10.1046/j.1365-2958.2003.03317.x.", "ArticleIdList": ["10.1046/j.1365-2958.2003.03317.x", "12519204"]}, {"Citation": "Gao M., Zhou J., Su Z., Huang Y. Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy. Protein Sci. 2017;26:2334\u20132341. doi: 10.1002/pro.3310.", "ArticleIdList": ["10.1002/pro.3310", "PMC5699490", "28960574"]}, {"Citation": "Punj V., Bhattacharyya S., Saint-Dic D., Vasu C., Cunningham E.A., Graves J., Yamada T., Constantinou A.I., Christov K., White B., et al. Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene. 2004;23:2367\u20132378. doi: 10.1038/sj.onc.1207376.", "ArticleIdList": ["10.1038/sj.onc.1207376", "14981543"]}, {"Citation": "Choi J.-H., Lee M.-H., Cho Y.-J., Park B.S., Kim S., Kim G.C. The bacterial protein azurin enhances sensitivity of oral squamous carcinoma cells to anticancer drugs. Yonsei Med. J. 2011;52:773\u2013778. doi: 10.3349/ymj.2011.52.5.773.", "ArticleIdList": ["10.3349/ymj.2011.52.5.773", "PMC3159935", "21786442"]}, {"Citation": "Yamada T., Goto M., Punj V., Zaborina O., Chen M.L., Kimbara K., Majumdar D., Cunningham E., Das Gupta T.K., Chakrabarty A.M. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc. Natl. Acad. Sci. USA. 2002;99:14098\u201314103. doi: 10.1073/pnas.222539699.", "ArticleIdList": ["10.1073/pnas.222539699", "PMC137843", "12393814"]}, {"Citation": "Bernardes N., Chakrabarty A.M., Fialho A.M. Engineering of bacterial strains and their products for cancer therapy. Appl. Microbiol. Biotechnol. 2013;97:5189\u20135199. doi: 10.1007/s00253-013-4926-6.", "ArticleIdList": ["10.1007/s00253-013-4926-6", "23644748"]}, {"Citation": "Yamada T., Mehta R.R., Lekmine F., Christov K., King M.L., Majumdar D., Shilkaitis A., Green A., Bratescu L., Beattie C.W., et al. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol. Cancer Ther. 2009;8:2947\u20132958. doi: 10.1158/1535-7163.MCT-09-0444.", "ArticleIdList": ["10.1158/1535-7163.MCT-09-0444", "19808975"]}, {"Citation": "Mehta R.R., Yamada T., Taylor B.N., Christov K., King M.L., Majumdar D., Lekmine F., Tiruppathi C., Shilkaitis A., Bratescu L., et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. Angiogenesis. 2011;14:355\u2013369. doi: 10.1007/s10456-011-9220-6.", "ArticleIdList": ["10.1007/s10456-011-9220-6", "21667138"]}, {"Citation": "Yamada T., Das Gupta T.K., Beattie C.W. p28-mediated activation of p53 in G2-M phase of the cell cycle enhances the efficacy of DNA damaging and antimitotic chemotherapy. Cancer Res. 2016;76:2354\u20132365. doi: 10.1158/0008-5472.CAN-15-2355.", "ArticleIdList": ["10.1158/0008-5472.CAN-15-2355", "26921335"]}, {"Citation": "CDG.  [(accessed on 14 February 2018)]; Available online:  http://www.cdgti.com/clinical-trials/"}, {"Citation": "Karpi\u0144ski T.M. Habilitation Thesis. Scientific Publisher of Pozna\u0144 University of Medical Sciences; Poznan, Poland: 2012. New Peptide (Entap) with Anti-Proliferative Activity Produced by Bacteria of Enterococcus Genus. (In Polish)"}, {"Citation": "Karpi\u0144ski T.M., Szkaradkiewicz A., Gamian A. New enterococcal anticancer peptide; Proceedings of the 23rd European Congress of Clinical Microbiology and Infectious Diseases; Berlin, Germany. 27\u201330 April 2013."}, {"Citation": "Sung W.S., Park Y., Choi C.H., Hahm K.S., Lee D.G. Mode of antibacterial action of a signal peptide, Pep27 from Streptococcus pneumoniae. Biochem. Biophys. Res. Commun. 2007;363:806\u2013810. doi: 10.1016/j.bbrc.2007.09.041.", "ArticleIdList": ["10.1016/j.bbrc.2007.09.041", "17900534"]}, {"Citation": "Lee D.G., Hahm K.-S., Park Y., Kim H.Y., Lee W., Lim S.C., Seo Y.K., Choi C.H. Functional and structural characteristics of anticancer peptide Pep27 analogues. Cancer Cell Int. 2005;5:21. doi: 10.1186/1475-2867-5-21.", "ArticleIdList": ["10.1186/1475-2867-5-21", "PMC1199608", "16004618"]}, {"Citation": "I-TASSER.  [(accessed on 16 February 2018)]; Available online:  http://zhanglab.ccmb.med.umich.edu/I-TASSER/"}, {"Citation": "Pangestuti R., Kim S.-K. Bioactive peptide of marine origin for the prevention and treatment of non-communicable diseases. Mar. Drugs. 2017;15:67. doi: 10.3390/md15030067.", "ArticleIdList": ["10.3390/md15030067", "PMC5367024", "28282929"]}, {"Citation": "Vijaya T. Anticancer, antimicrobial and antioxidant bioactive factors derived from marine fungal endophytes; a review. Indo Am. J. Pharm. Res. 2017;7:7313\u20137321."}, {"Citation": "Guzm\u00e1n-Rodr\u00edguez J.J., Ochoa-Zarzosa A., L\u00f3pez-G\u00f3mez R., L\u00f3pez-Meza J.E. Plant antimicrobial peptides as potential anticancer agents. BioMed Res. Int. 2015;2015:735087. doi: 10.1155/2015/735087.", "ArticleIdList": ["10.1155/2015/735087", "PMC4359852", "25815333"]}, {"Citation": "Negi B., Kumar D., Rawat D.S. Marine peptides as anticancer agents: A remedy to mankind by nature. Curr. Protein Pept. Sci. 2017;18:885\u2013904. doi: 10.2174/1389203717666160724200849.", "ArticleIdList": ["10.2174/1389203717666160724200849", "27455970"]}, {"Citation": "Karpi\u0144ski T.M., Szkaradkiewicz A.K. Human defensins. Arch. Biomed. Sci. 2013;1:1\u20135."}, {"Citation": "Deslouches B., Di P.Y. Antimicrobial peptides with selective antitumor mechanisms: Prospect for anticancer applications. Oncotarget. 2017;8:46635\u201346651. doi: 10.18632/oncotarget.16743.", "ArticleIdList": ["10.18632/oncotarget.16743", "PMC5542299", "28422728"]}, {"Citation": "Huang L., Chen D., Wang L., Lin C., Ma C., Xi X., Chen T., Shaw C., Zhou M. Dermaseptin-PH: A novel peptide with antimicrobial and anticancer activities from the skin secretion of the south american orange-legged leaf frog, Pithecopus (Phyllomedusa) hypochondrialis. Molecules. 2017;22:1805. doi: 10.3390/molecules22101805.", "ArticleIdList": ["10.3390/molecules22101805", "PMC6151546", "29064402"]}, {"Citation": "Dykhuizen D. Species numbers in bacteria. Proc. Calif. Acad. Sci. 2005;56(Suppl. 1):62\u201371.", "ArticleIdList": ["PMC3160642", "21874075"]}, {"Citation": "Schloss P.D., Girard R.A., Martin T., Edwards J., Thrash J.C. Status of the archaeal and bacterial census: An update. mBio. 2016;7:E00201-16. doi: 10.1128/mBio.00201-16.", "ArticleIdList": ["10.1128/mBio.00201-16", "PMC4895100", "27190214"]}, {"Citation": "Cheung R.C., Ng T.B., Wong J.H. Marine peptides: Bioactivities and applications. Mar. Drugs. 2015;13:4006\u20134043. doi: 10.3390/md13074006.", "ArticleIdList": ["10.3390/md13074006", "PMC4515606", "26132844"]}, {"Citation": "Daliri E.B.-M., Oh D.H., Lee B.H. Bioactive peptides. Foods. 2017;6:32. doi: 10.3390/foods6050032.", "ArticleIdList": ["10.3390/foods6050032", "PMC5447908", "28445415"]}, {"Citation": "Shin J.M., Gwak J.W., Kamarajan P., Fenno J.C., Rickard A.H., Kapila Y.L. Biomedical applications of nisin. J. Appl. Microbiol. 2016;120:1449\u20131465. doi: 10.1111/jam.13033.", "ArticleIdList": ["10.1111/jam.13033", "PMC4866897", "26678028"]}, {"Citation": "Sharifi M., Moridnia A., Mortazavi D., Salehi M., Bagheri M., Sheikhi A. Kefir: A powerful probiotics with anticancer properties. Med. Oncol. 2017;34:183. doi: 10.1007/s12032-017-1044-9.", "ArticleIdList": ["10.1007/s12032-017-1044-9", "28956261"]}, {"Citation": "Ruiz-Torres V., Encinar J.A., Herranz-L\u00f3pez M., P\u00e9rez-S\u00e1nchez A., Galiano V., Barraj\u00f3n-Catal\u00e1n E., Micol V. An updated review on marine anticancer compounds: The use of virtual screening for the discovery of small-molecule cancer drugs. Molecules. 2017;22:1037. doi: 10.3390/molecules22071037.", "ArticleIdList": ["10.3390/molecules22071037", "PMC6152364", "28644406"]}, {"Citation": "Gilad Y., Firer M., Gellerman G. Recent innovations in peptide based targeted drug delivery to cancer cells. Biomedicines. 2016;4:11. doi: 10.3390/biomedicines4020011.", "ArticleIdList": ["10.3390/biomedicines4020011", "PMC5344250", "28536378"]}]}], "History": [{"Year": "2018", "Month": "3", "Day": "23"}, {"Year": "2018", "Month": "4", "Day": "19"}, {"Year": "2018", "Month": "4", "Day": "19"}, {"Year": "2018", "Month": "5", "Day": "2", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "5", "Day": "2", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "5", "Day": "2", "Hour": "6", "Minute": "1"}, {"Year": "2018", "Month": "6", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["29710857", "PMC6027124", "10.3390/pharmaceutics10020054", "pharmaceutics10020054"]}}]}